Nature Communications (Nov 2022)
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
- Lucy B. Cook,
- Gillian O’Dell,
- Eleni Vourvou,
- Renuka Palanicawandar,
- Sasha Marks,
- Dragana Milojkovic,
- Jane F. Apperley,
- Sandra Loaiza,
- Simone Claudiani,
- Marco Bua,
- Catherine Hockings,
- Donald Macdonald,
- Aris Chaidos,
- Jiri Pavlu,
- Nichola Cooper,
- Sarah Fidler,
- Paul Randell,
- Andrew J. Innes
Affiliations
- Lucy B. Cook
- Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London
- Gillian O’Dell
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Eleni Vourvou
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Renuka Palanicawandar
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Sasha Marks
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Dragana Milojkovic
- Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London
- Jane F. Apperley
- Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London
- Sandra Loaiza
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Simone Claudiani
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Marco Bua
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Catherine Hockings
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Donald Macdonald
- Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London
- Aris Chaidos
- Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London
- Jiri Pavlu
- Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust
- Nichola Cooper
- Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London
- Sarah Fidler
- Section of Virology, Faculty of Medicine, Department of Infectious Diseases, Imperial College London
- Paul Randell
- Department of Infection and Immunity, North West London Pathology
- Andrew J. Innes
- Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London
- DOI
- https://doi.org/10.1038/s41467-022-34657-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 6
Abstract
SARS-CoV-2 vaccination has shown reduced efficacy in patients with haematological malignancies. Here, the authors show that a third vaccine is able to enhance SARS-CoV-2 antibody responses in most cases in a cohort of 381 patients with haematological malignancies.
